New angiogenesis targets
An international collaboration among researchers at the Karolinska Institute, Discovery Genomics Inc. and AngioGenetics AB has produced a set of previously unknown and potentially druggable targets in angiogenesis along with several matching antiangiogenic compounds.1
AngioGenetics was acquired by BioInvent International AB in 2007, and BioInvent now holds joint IP rights to the discoveries along with Discovery Genomics. The discoveries are the result of a 2002 partnership between AngioGenetics and Discovery Genomics.
The study, which combined a genetic screen with a chemical one, was published in Chemistry & Biology and was led by Mats Hellström, senior scientist at Karolinska and senior principal scientist at BioInvent.
Although genetic and pharmacological screens for angiogenesis targets have been